Irras AB is Sweden- based medical device company primarily engaged in develops and commercializes solutions that are designed to transform neurocritical care. Company focus on neurosurgical procedures, where excess cerebrospinal fluid (CSF) or toxic blood byproducts often need to be emergently drained and intracranial pressure (ICP) needs to be closely regulated.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company

Market Cap	182M 18.97M 16.54M 15.32M 14.34M 26.9M 1.79B 27.06M 70.44M 881M 71.21M 69.69M 3.06B	P/E 2023	-0.73x	P/E 2024	-1.89x
Enterprise Value	396M 41.29M 36M 33.34M 31.21M 58.54M 3.9B 58.89M 153M 1.92B 155M 152M 6.66B	EV / Sales 2023	5.26x	EV / Sales 2024	6.82x
Free-Float	3.55%	Yield 2023 *	-	Yield 2024	-

28/06/25	IRRAS AB Reports Earnings Results for the Full Year Ended December 31, 2024	CI
18/06/24	IRRAS AB Reports Earnings Results for the Full Year Ended December 31, 2023	CI
03/11/23	Irras has today its last day of trading on Nasdaq Stockholm before delisting	FW
24/10/23	IRRAS AB(OM:IRRAS) dropped from OMX Nordic All-Share Index	CI
24/10/23	IRRAS AB(OM:IRRAS) dropped from OMX Nordic Small Cap Index	CI
23/10/23	Irras Obtains Nasdaq Approval for Delisting in Stockholm	MT
20/10/23	Irras delisted from Nasdaq Stockholm with last trading day on November 3	FW
20/10/23	Sweden's Irras Files for Delisting as Privatization Nears Completion	MT
20/10/23	IR Holding Bidco calls for compulsory acquisition in Irras - applies for delisting	FW
16/10/23	Irras Obtains Extension for SEK20 Million Loan	MT
16/10/23	Irras extends SEK 20 million short-term loan	FW
02/10/23	Bidder controls 87.9 percent of the shares in Irras after completion of takeover bid	FW
19/09/23	Set-off issue only realistic option to avoid insolvency situation - Irra Board	FW

30/06/23	Bid for Irras below historical median premium - but also high risk of more fundraising - Afv(R)	FW
30/06/23	Bid for Irras below historical median premium - but also high risk of more fundraising - Afv	FW
22/05/23	Irra's Q1 sales below expectations - Redeye predicts new share issue and halves fair value	FW
22/05/23	Redeye lowers motivated value for Irras to SEK 0.15 (0.30)	FW
20/02/23	Redeye reiterates motivated value for Irras, but predicts capital raising this year	FW

20/10/23	IRRAS's application for delisting has been approved and the Board of Directors has resolved not to publish the interim report for the third quarter of 2023	AQ
20/10/23	NOTICE TO ATTEND THE EXTRAORDINARY GENERAL MEETING OF IRRAS AB	AQ
20/10/23	IR Holding Bidco Inc. requests compulsory buy-out and IRRAS applies for delisting	AQ
16/10/23	IRRAS publishes prospectus	AQ
15/10/23	IRRAS has extended maturity date for its SEK 20 million short-term loan	AQ

Manager	Title	Age	Since
Will Martin CEO	Chief Executive Officer	51	01/07/2021
Griffen Stapp DFI	Director of Finance/CFO	40	17/06/2021
Sten Gustafsson IRC	Investor Relations Contact	-	09/03/2021

IRRAS AB Stock OTC Markets

Stocks

IRRA.F

SE0008321202

Medical Equipment, Supplies & Distribution

Valuation: IRRAS AB

Latest news : IRRAS AB

Analysts' recommendations: IRRAS AB

Press Releases: IRRAS AB

Quotes and Performance

Managers and Directors: IRRAS AB

Medical Devices & Implants

Financials

Company Profile

Director	Title	Age	Since
Kleanthis Xanthopoulos BRD	Director/Board Member	68	01/06/2015
Marios Fotiadis CHM	Chairman	53	18/08/2020
Inger Gunnel Anita Tollstadius BRD	Director/Board Member	71	01/09/2017

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
IRRAS AB	-15.36%	-27.68%	-	-	16.9M
STRYKER CORPORATION	+2.21%	-1.41%	-17.54%	+4.57%	118B
SMITH & NEPHEW PLC	-0.66%	-1.01%	+5.44%	-10.39%	12.72B
GLAUKOS CORPORATION	+2.57%	+3.05%	+27.69%	+92.97%	7.67B
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD.	+0.48%	-1.28%	-46.91%	-72.29%	4.07B
DOUBLE MEDICAL TECHNOLOGY INC.	+1.51%	+2.35%	+18.57%	+34.36%	2.56B
BEIJING BALANCE MEDICAL TECHNOLOGY CO.,LTD.	+0.94%	+4.16%	-14.60%	-16.91%	1.78B
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD.	-0.21%	-2.45%	+2.33%	-19.56%	1.59B
L&C BIO CO.,LTD	+5.36%	+0.12%	+184.99%	+154.14%	1.41B
Average	-0.35%	+1.04%	+20.00%	+20.86%	18.72B
Weighted average by Cap.	+1.91%	+0.76%	-11.30%	+7.14%

	2023	2024
Net sales	42.88M 4.48M 3.9M 3.61M 3.38M 6.35M 422M 6.38M 16.62M 208M 16.8M 16.44M 722M	57.98M 6.05M 5.28M 4.89M 4.58M 8.58M 571M 8.63M 22.47M 281M 22.72M 22.23M 976M
Net income	-209M -21.8M -19.01M -17.61M -16.48M -30.91M -2.06B -31.1M -80.95M -1.01B -81.85M -80.09M -3.52B	-95.98M -10.02M -8.74M -8.09M -7.57M -14.2M -945M -14.29M -37.2M -465M -37.61M -36.8M -1.62B
Net Debt	43.85M 4.58M 3.99M 3.7M 3.46M 6.49M 432M 6.53M 16.99M 213M 17.18M 16.81M 738M	214M 22.32M 19.46M 18.02M 16.87M 31.64M 2.11B 31.83M 82.85M 1.04B 83.77M 81.97M 3.6B